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Nonalcoholic fatty liver disease (NAFLD) is the most common
chronic liver disorder and is strongly associated with obesity and
type 2 diabetes. Currently, there is no approved pharmacological
treatment for this disease, but improvement of insulin resistance
using peroxisome proliferator-activated receptor-γ (PPARγ) ago-
nists, such as thiazolidinediones (TZDs), has been shown to reduce
steatosis and steatohepatitis effectively and to improve liver func-
tion in patients with obesity-related NAFLD. However, this ap-
proach is limited by adverse effects of TZDs. Recently, we have
identified fibroblast growth factor 1 (FGF1) as a target of nuclear
receptor PPARγ in visceral adipose tissue and as a critical factor in
adipose remodeling. Because FGF1 is situated downstream of
PPARγ, it is likely that therapeutic targeting of the FGF1 pathway
will eliminate some of the serious adverse effects associated with
TZDs. Here we show that pharmacological administration of
recombinant FGF1 (rFGF1) effectively improves hepatic inflamma-
tion and damage in leptin-deficient ob/ob mice and in choline-
deficient mice, two etiologically different models of NAFLD. Hepatic
steatosis was effectively reduced only in ob/ob mice, suggesting
that rFGF1 stimulates hepatic lipid catabolism. Potentially adverse
effects such as fibrosis or proliferation were not observed in these
models. Because the anti-inflammatory effects were observed in
both the presence and absence of the antisteatotic effects, our find-
ings further suggest that the anti-inflammatory property of rFGF1 is
independent of its effect on lipid catabolism. Our current findings
indicate that, in addition to its potent glucose-lowering and insulin-
sensitizing effects, rFGF1 could be therapeutically effective in the
treatment of NAFLD.
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Nonalcoholic fatty liver disease (NAFLD) is the most commonchronic liver disease in developed countries and is strongly
associated with obesity and type 2 diabetes (1). NAFLD refers to
a wide spectrum of liver disorders ranging from simple fatty liver
(steatosis) to nonalcoholic steatohepatitis (NASH) with increased
risk of developing progressive fibrosis, cirrhosis, and liver cancer (2).
Treatment options for NAFLD are limited and are directed
mainly at weight loss or pharmacological improvement of insulin
resistance (3). Although no pharmacologic therapy has been ap-
proved, the thiazolidinedione (TZD) class of insulin sensitizers
has been demonstrated to improve steatosis, steatohepatitis, and
liver function in mice and patients with NAFLD (1). TZDs improve
insulin sensitivity through activation of nuclear receptor peroxisome
proliferator-activated receptor-gamma (PPARγ), which reduces in-
sulin resistance in adipose tissue, liver, and skeletal muscle (4).
The exact mechanism by which PPARγ exerts its beneficial effects
on NAFLD is not completely understood, but it is believed that
improved hepatic insulin sensitivity enhances lipid oxidation and
reduces hepatic lipogenesis, thereby reducing steatosis (5). In ad-
dition, increased peripheral insulin sensitivity may reduce lipolysis
in white adipose tissue and thereby limit ectopic fat accretion.
PPARγ and its activators also have broad anti-inflammatory
effects. On one hand, PPARγ has been shown to attenuate the
expression and secretion of proinflammatory cytokines (in-
cluding IL-1β and TNF-α) associated with M1 macrophages (6);
on the other hand, it reduces macrophage activity via trans-
repression of NF-κB (7). Despite their efficacy in glycemic
control and reduction of steatosis, TZDs are associated with
various serious adverse side effects, including weight gain, fluid
retention, osteoporosis, and cardiovascular toxicity, which have
strongly limited their clinical use (4). These limitations highlight
the need for novel approaches such as more selective PPARγ
agonists or direct activation of downstream targets.
Recently we have identified fibroblast growth factor 1 (FGF1)
as a target of PPARγ in visceral adipose tissue and as a critical
factor in adipose remodeling (8). Mice with an FGF1 deficiency
displayed a severe diabetic phenotype with increased inflammation
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and fibrosis in adipose tissue. Conversely, pharmacological
treatment with recombinant FGF1 (rFGF1) has a potent insulin-
sensitizing effect at the systemic level, and in the liver it effec-
tively reduces steatosis in ob/ob mice (9). It remains unclear,
however, if and to what extent the hepatic effects of FGF1 are
direct or indirect.
In this study we used two etiologically different models of
NAFLD to determine the mechanism by which rFGF1 improves
liver disease: leptin-deficient ob/ob mice, which develop steatosis
primarily through excessive food intake, and mice with a dietary
choline deficiency, which develop steatosis primarily as a result
of a defect in hepatic lipid catabolism (10). Interestingly, we found
that rFGF1 effectively reverses steatosis in ob/ob mice but not in
mice with a dietary choline deficiency, suggesting that rFGF1
stimulates hepatic lipid catabolism. rFGF1 treatment improved
steatohepatitis and plasma alanine transaminase activity (ALT) in
both models, indicating that the effects of rFGF1 on hepatic
inflammation and liver function are independent of its anti-
steatotic properties. Together our results provide insight into the
mechanism by which rFGF1 improves NAFLD and highlight its
potential therapeutic value in the treatment of different aspects
of liver disease.
Results
rFGF1 Has Potent Antisteatotic Effects in ob/ob Mice. To investigate
the mechanism by which rFGF1 exerts its effects on NAFLD/
NASH, we treated ob/ob mice for a period of 12 d with rFGF1
(0.5 mg/kg i.p. every 3 d). Twelve days of treatment significantly
reduced hepatic levels of triglycerides and liver mass without
affecting body weight (Fig. 1 A–C). Histological examination
using H&E staining confirmed the antisteatotic effect of rFGF1
but also revealed that this reduction in hepatic lipids occurred in
a zonated fashion (Fig. 1D). To further explore this zonation
effect, we used the central vein marker glutamine synthetase
(GS), which indicated pronounced reduction of steatosis in the
periportal zone, but steatosis in the pericentral region was not
significantly affected by rFGF1 treatment (Fig. 1 E–G).
rFGF1 Suppresses Hepatic Inflammation in ob/ob Mice. Hepatic
steatosis can develop into NASH, which is more serious and is
characterized by hepatic inflammation and fibrosis. In addition
to its potent antisteatotic action, rFGF1 also suppressed hepatic
inflammation in ob/ob mice as indicated by reduced mRNA ex-
pression of a range of hepatic inflammatory markers (Fig. 2
A–D). Twelve days of treatment with rFGF1 significantly reduced
the expression of the proinflammatory M1 markers monocyte
chemotactic protein 1 (MCP-1) and TNFα and the macrophage/
Kupffer markers F4/80, CD68, and CD11c (Fig. 2A). After 5 wk
of treatment with rFGF1 these markers were reduced even
further, and significant reductions also were observed for the
proinflammatory cytokine IL1β, the cell adhesion molecules
E-selectin, intracellular adhesion molecule 1 (ICAM-1), and vas-
cular cell adhesion molecule 1 (VCAM-1), which are activated by
TNFα and IL-1β, and the macrophage marker CD11b (Fig. 2B). In
contrast, hepatic expression of the anti-inflammatory M2 markers
IL-10, CD163, and Arginase 1 (Arg1) was not affected by rFGF1
administration (except for CD206 in the mice treated for 5 wk)
(Fig. S1 A–D), indicating that rFGF1 exerts its anti-inflammatory
effect mainly by suppressing proinflammatory M1 markers in liver.
Reduced hepatic inflammation also was observed by histopatho-
logical and protein analysis, indicating lower scores on lobular in-
flammation (Table S1) and reduced levels of TNF-α (Fig. 2 C–E).
rFGF1 Reduces Endothelial VCAM-1 Expression. To investigate how
rFGF1 suppresses hepatic inflammation, we examined its po-
tential to modulate cytokine- or endotoxin-induced inflamma-
tory gene expression in several cell models representing different
hepatic cell types (hepatocytes, macrophages, and endothelial
cells). We did not find a role for hepatocytes, the major paren-
chymal cell type in liver, in the anti-inflammatory effect of rFGF1
because rFGF1 did not affect basal or slightly increased cytokine-
induced (i.e., TNFα/IL1β) inflammatory gene expression (Fig. S2).
We next questioned if rFGF1 could mediate its anti-inflammatory
effect through the modulation of endotoxin-induced activation of
macrophages or endothelial cells. We examined the effect of
rFGF1 preincubation on the activation of RAW264.7 macrophage
cells and human umbilical vein endothelial cells (HUVECs) by
LPS. In RAW264.7 cells, rFGF1 pretreatment did not interfere
with basal or endotoxin-induced inflammatory gene expression
(Fig. S2). In contrast, a significant reduction in the expression of
VCAM-1 was observed in HUVECs in response to LPS (Fig.
3A). Basal and endotoxin-induced gene expression of MCP-1,
ICAM-1, and E-selectin was unaffected by rFGF1 pretreatment in
HUVECs (Fig. 3 B–D). Because VCAM-1 has been implicated in
leukocyte recruitment, it is possible that the anti-inflammatory
effects of rFGF1 are mediated through reduced endothelial
VCAM-1 expression.
The Antisteatotic Effects of rFGF1 Are Absent in a Choline-Deficient
Model of Steatosis. Steatosis results from an imbalance in hepatic
lipid metabolism. Hepatic fatty acid synthesis and triglyceride
accumulation occur predominantly in the pericentral zone, whereas
fatty acid oxidation and secretion [very-low-density lipoprotein
(VLDL) production] are associated more with the periportal
Fig. 1. rFGF1 reduces hepatic steatosis in ob/ob mice. (A–C) A 12-d rFGF1
treatment (0.5 mg/kg i.p. every 72 h) of ob/ob mice does not affect body
weight (A) but does reduce liver mass (B) and hepatic triglyceride levels (C)
(n = 6; unpaired t test with Welch’s correction). (D and E) Histological visual-
ization of steatosis in serial liver sections stained with H&E (D) and the central
vein marker GS (E) combined with H&E. C, central vein; P, portal area. (Scale
bars: 300 μm.) (F) Quantitation of zonal distribution of steatosis in liver (n = 6
slides per group; two-way ANOVA). PC, pericentral zone; PP, periportal zone.
(G) High magnification H&E-stained liver sections show reduced steatosis at
the periportal zone in rFGF1 treated animals (scale bars: 90 μM). *P < 0.05,
**P < 0.01.
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zone (11). Our observation that rFGF1 primarily reduces steatosis
in the periportal zone thus suggested that rFGF1 improves hepatic
lipid catabolism (i.e., oxidation and/or secretion). To investigate
further how rFGF1 exerts its antisteatotic effects, we used a choline-
deficient, L-amino acid–defined (CDAA) diet, a commonly used
rodent model for steatosis (10). In contrast to ob/ob mice and diet-
induced obesity (DIO) models of steatosis, which have increased
hepatic lipid accumulation through excessive food intake, choline
deficiency causes a defective hepatic lipid catabolism, resulting in
steatosis in the absence of obesity or insulin resistance (10).
Mice were challenged with the CDAA or control choline-
supplemented, L-amino acid–defined (CSAA) diet for 3 or 6 wk,
and the preventive effect of rFGF1 (0.5 mg/kg administered i.p.
every 3 d) on the development of NAFLD/NASH was moni-
tored. Body weights and white adipose mass of control and
rFGF1-treated mice increased at similar rates and were not
significantly different as compared with the dietary control group
(Fig. 4 A and B). Liver mass, as a percentage of body weight,
increased from ∼4% to ∼6% in the first 3 wk but remained stable
at 6 wk (Fig. 4C). As expected, hepatic triglyceride levels in the
CDAA-challenged mice increased progressively over time as
compared with the CSAA control mice, but no effect of rFGF1
was observed on either liver mass or hepatic triglycerides (Fig. 4
C and D). These findings were supported by histological ex-
amination using H&E and Oil red O staining (Fig. 4 E and F
and Figs. S3 and S4). GS staining further indicated a clear
periportal localization of the steatosis in the CDAA model
similar to previous reports (Fig. 4G) (12). Together, these re-
sults suggest that the antisteatotic effects of rFGF1 are de-
pendent on the catabolic processes that are defective in the
CDAA model.
rFGF1 Suppresses Hepatic Inflammation Independent of Its Antisteatotic
Effects.Because rFGF1 did not affect steatosis in the CDAAmodel,
this model allowed us to investigate whether the anti-inflammatory
properties of rFGF1 are dependent on its antisteatotic properties.
After a 3-wk CDAA challenge, significant reductions in the mRNA
expression of MCP-1, TNFα, ICAM-1, VCAM-1, and CD11c were
observed in rFGF1-treated mice as compared with CDAA control
mice (Fig. 5A). In addition, a trend toward decreased expression
was observed for IL-1β and E-selectin in rFGF1-treated mice. Re-
duced hepatic inflammation was further confirmed by histopatho-
logical and protein analysis, indicating a reduction in the number of
inflammatory foci in the liver (Fig. 5B and Table S2) and reduced
levels of MCP-1 protein (Fig. 5C). These data show that rFGF1
exerts its anti-inflammatory effect in the liver independently from its
antisteatotic effect. After a 6-wk CDAA challenge, however, mRNA
expression of inflammatory markers were no longer reduced (and in
the case of E-selectin were even increased) by rFGF1 treatment (Fig.
S5). In addition, no effect of rFGF1 on anti-inflammatory M2
marker expression was observed (Fig. S1 C and D). Histopatho-
logical analysis further indicated that lobular inflammation was in-
creased in the rFGF1-treated mice as compared with the CDAA
control mice (Table S3).
Interestingly, rFGF1 also prevented the increase in plasma
ALT activity, a marker for liver damage, after a 3 wk CDAA
challenge, and a similar trend was seen after 6 wk (Fig. 5D and
Fig. S5). rFGF1 may thus have hepato-protective properties be-
yond its antisteatotic and anti-inflammatory properties. In line with
this finding, it has been reported previously that FGF1/FGF2
double-knockout mice exhibit increased levels of ALT after tetra-
chloride-induced hepatic injury (13). Together, our results show
that in the CDAA model rFGF1 can prevent liver damage, as
reflected by reduced plasma levels of ALT, and that it can delay but
not prevent hepatic inflammation.
rFGF1 Does Not Induce Hepatic Fibrosis or Proliferation. Potential
adverse effects of FGFs are fibrosis and proliferation. Previous
studies have suggested that FGF1 has a role in promoting he-
patic fibrosis. Increased expression of FGF1/FGFRc was observed
in a rat model of experimental pulmonary fibrosis and in patients
with idiopathic pulmonary fibrosis, respectively (14, 15). Con-
versely, loss of FGF1 and FGF2 in mice resulted in decreased liver
fibrosis upon exposure to carbon tetrachloride (13). To assess the
effect of rFGF1 on the development of hepatic fibrosis, liver
samples from ob/ob mice treated with rFGF1 for 5 wk were
A
B
C
D
E
Fig. 2. rFGF1 suppresses hepatic inflammation in ob/ob mice. (A and B)
Gene expression of inflammatory markers in livers of ob/ob mice treated
with rFGF1 for 12 d (A) or for 5 wk (B). (C–E) Western blot analysis of TNF-α
protein levels in the livers of rFGF1-treated ob/ob mice at 12 d (C) or 5 wk
(D). (E) Quantitation of C and D. (n = 6–8; Mann–Whitney test.) *P < 0.05,
**P < 0.01, ***P < 0.001.
A B
C D
Fig. 3. Effect of rFGF1 on activation of HUVEC endothelial cells. The ex-
pression of VCAM-1 (A), ICAM-1 (B), MCP-1 (C), and E-selectin (D) in HUVECs
after activation by LPS (n = 3; *P < 0.05; Mann–Whitney test).
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analyzed for the expression of fibrogenic maker genes. The expres-
sion of TGF-β1, which has been shown to accelerate liver fibrogenesis
by promoting hepatic stellate cell transformation and activation of the
expression of extracellular matrix genes (16), was significantly re-
duced in rFGF1-treated ob/ob mice as compared with control mice
(Fig. 6A). The expression of collagen-α1, αSMA, and TIMP-1,
however, was not significantly different. Also, no significant differ-
ences in the expression of fibrogenic genes or collagen deposition
were observed between control and rFGF1-treated mice after a 3- or
6-wk CDAA challenge, respectively (Fig. 6 B–D and Fig. S6). Finally,
we observed a significant reduction in the expression of the pro-
liferation marker Ki-67 by rFGF1 after a 3-wk CDAA challenge, but
no difference was observed after 6 wk (Fig. 6 E and F). These
findings were supported by histopathological analyses (Table S4).
Together, these results suggest that rFGF1 has no adverse effects on
hepatic fibrosis or proliferation.
Discussion
Here we show that pharmacological administration of rFGF1
effectively improves obesity-related steatosis, hepatic inflamma-
tion, and hepatic damage. Our findings further suggest that these
effects are at least partially independent, because the anti-in-
flammatory effects were observed in both the presence and ab-
sence of anti-steatotic effects.
Although no pharmacological treatment has currently been
approved for NAFLD/NASH, insulin sensitizers and antioxidative
treatment strategies with vitamin E are among the best-established
approaches (1). However, both these approaches have long-term
safety issues, and there is only limited evidence of improvement in
cirrhotic patients (1, 17). Vitamin E treatment is associated with
increased mortality, and TZDs have been associated with various
adverse effects including weight gain, fluid retention, and osteo-
porosis, complicating their clinical use (4, 18). In addition, TZDs
are contraindicated in patients with symptomatic chronic heart
failure (19). Current strategies for novel PPARγ-based treat-
ments therefore are directed at developing selective receptor
modulators with reduced adverse effects or at activation of se-
lective downstream targets (20).
Recently, we have identified FGF1 as a target of nuclear re-
ceptor PPARγ in visceral adipose tissue and as a critical factor in
adipose function, insulin resistance, and the development of type
2 diabetes (8, 9). When challenged with a high-fat diet, mice
lacking FGF1 display aberrant adipose expansion characterized
by reduced angiogenesis and increased adipose inflammation
and fibrosis, resulting in ectopic fat accumulation in the liver and
in insulin resistance (8). Conversely, pharmacological administration
of rFGF1 improved hyperglycemia, insulin sensitivity, and steatosis
in mouse models of obesity (9).
A B
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F
G
D
Fig. 4. rFGF1 does not reduce steatosis in mice with a dietary choline de-
ficiency. (A–D) rFGF1 does not affect body weight (A), epididymal white
adipose tissue (eWAT) mass (B), liver mass (C), or hepatic triglyceride (TG)
levels (D) in mice challenged for 3 or 6 wk with a CDAA or on a control CSAA
diet (n = 8 or 10 mice per group; one-way ANOVA). (E–G) Histological visu-
alization of steatosis in serial liver sections after a 3-wk CDAA challenge,
without (Left) or with (Right) rFGF1, stained with H&E (E), Oil red O (F), or
the central vein marker GS combined with H&E (G). C, central vein; P, portal
vein. (Scale bars: 300 μm.) *P < 0.05, **P < 0.01.
A
B
C D E
Fig. 5. rFGF1 suppresses hepatic inflammation in mice with a dietary cho-
line deficiency. (A) Effect of rFGF1 on the expression of inflammatory genes
in the livers of mice challenged for 3 wk with a CDAA diet or on a CSAA diet
(n = 8 or 10; one-way ANOVA). (B) Histological visualization of inflammation
in H&E-stained liver sections. Aggregations of lymphocytes, indicating lob-
ular inflammation, are indicated by arrows. C, central vein; P, portal area. (C)
Western blot analysis of MCP-1 protein levels. (D) Quantitation of C (un-
paired t test with Welch’s correction). (E) ALT activity (n = 3 or 5; one-way
ANOVA). *P < 0.05, **P < 0.01.
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Two other members of the FGF family, the endocrine hormones
FGF15/19 and FGF21, also have been shown to improve hy-
perglycemia, insulin resistance, and steatosis (21). The effects of
FGF15/19 are mediated directly through activation of FGF re-
ceptor 4 (FGFR4) and its coreceptor β-klotho in the liver (19,
20). FGF15/19 is produced in the ileum, where its expression is
controlled by the bile acid-activated nuclear receptor FXR, and
subsequently is secreted into the circulation (22, 23). In the liver,
FGF15/19 suppresses bile acid synthesis and gluconeogenesis
(22, 24, 25). Although we have not observed effects of FGF1 on
bile acid homeostasis, it is possible that some of its metabolic
effects are mediated directly through hepatic FGFR4 activation,
because FGF1 acts as a universal ligand for all FGFRs. In con-
trast to FGF15/19, the glycemic effects of FGF1 and FGF21 are
dependent on FGFR1 activation in adipose tissue (9, 26). FGF21
also can alleviate endoplasmic reticulum stress-induced hepatic
steatosis by acting as a metabolic effector of the unfolded protein
response (27). Whether these effects are directly mediated through
FGFR activation in the liver and whether FGF1 and FGF15/19 act
through the same pathway is not known.
In contrast to ob/ob mice and DIO models of steatosis, we did
not observe an improvement in steatosis in the choline-deficient
model. The difference in the etiology of steatosis in these models
gives a clue to the mechanism of action of FGF1. The ob/ob mice
and DIO mice have increased hepatic lipid accumulation caused
by excessive food intake, but a choline deficiency causes defective
hepatic β-oxidation and the production of VLDL, resulting in
steatosis in the absence of obesity or insulin resistance (10, 28).
These differences in the pathophysiology of steatosis were clearly
reflected in the zonal distribution of lipids in these models. Steatosis
in ob/ob mice was located primarily in the pericentral region but
in the CDAA model was present mainly in the periportal region.
Hepatic zonation plays an important role in the segregation of
the different metabolic pathways in the liver (11, 29). Hepatic
fatty acid synthesis and triglyceride accumulation occur pre-
dominantly in the pericentral zone, whereas catabolic processes
such as fatty acid oxidation and fatty acid secretion (VLDL
production) are associated more with the periportal zone (11). Our
observation that reduction of steatosis by rFGF1 is limited to the
periportal zone thus suggests that rFGF1 acts by improving hepatic
lipid catabolism (i.e., oxidation and/or secretion).
Hepatic lipid metabolism and inflammation are tightly linked
processes, and both are known to exacerbate insulin resistance
(30). The accumulation of toxic lipid species and their metabo-
lites, such as saturated free fatty acids, free cholesterol, and the
sphingolipid ceramide, has been shown to exert an inflammatory
response by activating Bax protein translocation, which in turn
triggers lysosomal and mitochondrial permeabilization, the pro-
duction of reactive oxygen species, and apoptosis (31). This pro-
cess, called “lipotoxicity,” promotes the activation of Kupffer cells
(specialized macrophages in the liver) and exacerbates insulin
resistance and the progression of NASH (32). Our results show
that rFGF1 effectively suppresses hepatic inflammation both in
ob/ob mice and choline-deficient mice, as indicated by significant
reductions in the expression of the proinflammatory M1 markers
MCP-1 and TNFα. Interestingly, the anti-inflammatory effect of
rFGF1 became more pronounced with prolonged (5-wk) treatment
in ob/ob mice, as evidenced by the further suppression of M1
markers and also of cell adhesion markers (E-selectin, VCAM-1,
ICAM-1) and macrophage/Kupffer cell markers (F4/80, CD68,
CD11b, and CD11c). rFGF1 also suppressed hepatic inflamma-
tion after a 3-wk challenge with a choline-deficient diet, but this
effect was no longer observed at 6 wk. It is possible that the anti-
inflammatory effect of rFGF1 is achieved only in the presence of
relatively low levels of hepatic lipids (e.g., 3-wk CDAA) and that
when levels of hepatic lipids become progressively higher (e.g.,
6-wk CDAA), the anti-inflammatory effect of rFGF1 is mitigated
because of lipotoxicity.
Our in vitro data suggest that rFGF1 does not suppress in-
flammation through a direct effect on hepatocytes or through
macrophage activation. However, we did find a strong suppres-
sion of VCAM-1 expression in HUVEC endothelial cells. Sinu-
soidal endothelial cells play a major role in hepatic inflammation
through their involvement in adhesion molecule-mediated re-
cruitment of leukocytes (33). It was shown previously that FGF1
suppresses transendothelial leukocyte migration by reducing the
expression of several endothelial adhesion molecules, including
VCAM-1 (34). Endothelial cells in normal liver express little or
no VCAM-1, but VCAM-1 is highly induced during conditions
of steatohepatitis (35). We speculate, based on these findings,
that rFGF1 in vivo decreases leukocyte recruitment by re-
ducing endothelial VCAM-1 and thereby suppresses hepatic
inflammation.
Together, our findings show that FGF1 has therapeutic po-
tential in the treatment of NAFLD and NASH. Because FGF1 is
situated downstream of PPARγ, it is likely that therapeutic tar-
geting of FGF1 will eliminate some of the adverse effects asso-
ciated with TZDs that are mediated through direct activation
of PPARγ.
Experimental Procedures
Animals.Mice were housed and handled according to institutional guidelines
complying with Dutch legislation. All experiments were approved by the
Ethical Committee for Animal Experiments, University of Groningen, Groningen,
The Netherlands. Animals used in this study were male wild-type and ob/obmice
on a C57BL/6J genetic background (Charles River), between 8 and 12 wk of age.
Animals were housed in a light- and temperature-controlled facility (lights on
from 7:00 AM to 7:00 PM, 21 °C). All mice received a standard laboratory
chow (RMH-B; Hope Farms) and acidified water ad libitum.
Animal Experiments. Choline deficiency was induced by a 3- or 6-wk challenge
with a CDAA (518753; Dyets Inc.) or a CSAA control diet (518754; Dyets Inc.).
Mice were treated with vehicle (PBS) or rFGF1 (0.5 mg/kg) (ProSpec) by i.p.
injection starting 3 d before the dietary intervention and then every 72 h for 3
or 6wk.Micewere killed by cardiac puncture after anesthesiawith isoflurane.
Terminal blood samples were collected in EDTA-coated tubes. Tissues were
A
C
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Fig. 6. FGF1 does not promote hepatic fibrosis and proliferation in ob/ob
mice or in choline-deficient mice. (A and B) Fibrogenic gene expression in
ob/ob mice treated for 5 wk with rFGF1 (n = 6 or 8; Mann–Whitney test) (A)
and in mice challenged for 3 wk (n = 5 or 6) with a CDAA diet (n = 8–10) or on
a CSAA (n = 5 or 6; one-way ANOVA) (B). (C) Histological visualization of
fibrosis in liver sections stained with Sirius red from mice challenged for 6 wk
with a CSAA diet or on a CDAA diet with or without rFGF1. Arrows indicate
pericentral and hepatocyte collagen deposition. (Scale bars: 500 μm.) (D)
Quantitation of fibrosis in liver sections from mice challenged for 6 wk with
a CSAA diet or on a CDAA diet with or without rFGF1 (n = 5 slides per group;
one-way ANOVA). (E and F) Expression of Ki-67 in mice fed the CDAA diet for
3 wk (E) or 6 wk (F) (n = 5 or 6). *P < 0.05, **P < 0.01, ***P < 0.001.
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collected and frozen in liquid nitrogen or were processed for histology.
Hepatic lipids were extracted according to Bligh and Dyer (36). Triglycerides
were determined using the Trig/GB kit (11877771; Roche) and absorption at
540 nm. Plasma was obtained by centrifugation at 2,000 × g for 10 min and
was used for the determination of ALT activity using the spinreact GOT-GPT
kit (1002500; Girona).
Histological Analysis and Immunohistochemistry. For microscopic examination,
tissues were fixed in 4% (wt/vol) formaldehyde in PBS, embedded in paraffin,
sectioned at 4 μm, and stained with H&E. Liver fibrosis was assessed by Sirius
red staining. Liver steatosis was visualized by Oil red O staining of liver
cryosections. To determine zonation, GS staining was used for central vein
localization (37). Briefly, sections were deparaffinized in xylene and rehy-
drated in a series of graded alcohol-washing steps. Antigen retrieval was
conducted by gently boiling of sections in 1 mM EDTA solution, pH 8.0, for
15 min. Endogenous HRP activity was blocked in 0.3% H2O2; 10% (vol/vol)
normal goat serum in 1% BSA PBS solution was used to block nonspecific
binding before antibody incubation. Anti-GS (mouse IgG2a) (610518; BD
Biosciences) primary antibody was incubated overnight at 4 °C, washed with
PBS, followed by incubation with HRP-conjugated goat anti-mouse IgG
(R40101; Invitrogen) for 1 h at room temperature. AEC (3-amino-9-ethyl-
carbazole) reagent (Sigma) containing 0.3% H2O2 was used for visualization.
Hepatic steatosis and steatohepatitis were assessed in an unbiased manner
by two board-certified pathologists (including A.d.B.). Hepatic steatosis and
inflammation were graded in H&E-stained liver sections by using an adapted
version of the NAFLD activity scoring system developed by Kleiner et al. (38).
For quantitation of steatosis, H&E- and GS-stained sections (six slides for each
group) were randomly selected. Next, three or four pericentral or periportal
areas on each section were selected and quantified for steatosis using ImageJ.
Gene-Expression Analysis. Total RNA was isolated from the liver using Tri re-
agent (Life Technologies) and was reverse transcribed into cDNA using Moloney
murine leukemia virus, random primers, and dNTP according to standard pro-
cedures. For quantitative PCR (qPCR), cDNAwas amplified usingHi-ROX SensiMix
SYBR Green (Bioline) and the StepOnePlus Real-Time PCR System (Applied
Biosystems). Primers used for qPCR are listed in Table S5. U36B4was used as the
house-keeping gene in all PCR analyses, and the ΔΔCt method was used
for quantification.
Statistical Analysis. All values are given as means ± SD. The two-tailed unpaired
Student’s t test with Welch’s correction, nonparametric Mann–Whitney test, or
one-way or two-way ANOVA analysis with Holm–Sidak’s multiple comparison
test were used for statistical analysis. Significance was indicated as *P < 0.05,
**P < 0.01, ***P < 0.001.
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